BioStock: Advancements for Elicera in 2022 open for intensive clinical year
In 2022, Elicera Therapeutics – the only Swedish R&D company developing CAR T-cell therapies in Sweden – advanced on several fronts. The company received a total of more than SEK 30 million in grants which finance, among other things, its clinical activities. In addition to the company taking important steps in business development, new positive research results with the company’s oncolytic virus were also presented. Furthermore, Elicera recently applied to start the first clinical trial with the company’s CAR T treatment ELC-301. If approved, it would pave the way for an intensive clinical year in 2023.
Read the article about Elicera Therapeutics at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/